249 related articles for article (PubMed ID: 34730109)
1. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation.
Persaud SP; Ritchey JK; Kim S; Lim S; Ruminski PG; Cooper ML; Rettig MP; Choi J; DiPersio JF
J Clin Invest; 2021 Dec; 131(24):. PubMed ID: 34730109
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
3. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
[TBL] [Abstract][Full Text] [Related]
5. Alloengraftment without significant toxicity or GVHD in CD45 antibody-drug conjugate-conditioned Fanconi anemia mice.
Saha A; Palchaudhuri R; Lanieri L; Hyzy S; Riddle MJ; Panthera J; Eide CR; Tolar J; Panoskaltsis-Mortari A; Gorfinkel L; Tkachev V; Gerdemann U; Alvarez-Calderon F; Palato ER; MacMillan ML; Wagner JE; Kean LS; Osborn MJ; Kiem HP; Scadden DT; Olson LM; Blazar BR
Blood; 2024 May; 143(21):2201-2216. PubMed ID: 38447038
[TBL] [Abstract][Full Text] [Related]
6. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
[TBL] [Abstract][Full Text] [Related]
7. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease.
Choi J; Cooper ML; Staser K; Ashami K; Vij KR; Wang B; Marsala L; Niswonger J; Ritchey J; Alahmari B; Achilefu S; Tsunoda I; Schroeder MA; DiPersio JF
Leukemia; 2018 Nov; 32(11):2483-2494. PubMed ID: 29691471
[TBL] [Abstract][Full Text] [Related]
8. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice.
Saha A; Hyzy S; Lamothe T; Hammond K; Clark N; Lanieri L; Bhattarai P; Palchaudhuri R; Gillard GO; Proctor J; Riddle MJ; Panoskaltsis-Mortari A; MacMillan ML; Wagner JE; Kiem HP; Olson LM; Blazar BR
Blood; 2022 Mar; 139(11):1743-1759. PubMed ID: 34986233
[TBL] [Abstract][Full Text] [Related]
9. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
10. Antibody based conditioning for allogeneic hematopoietic stem cell transplantation.
Saha A; Blazar BR
Front Immunol; 2022; 13():1031334. PubMed ID: 36341432
[TBL] [Abstract][Full Text] [Related]
11. IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.
Choi J; Ziga ED; Ritchey J; Collins L; Prior JL; Cooper ML; Piwnica-Worms D; DiPersio JF
Blood; 2012 Nov; 120(19):4093-103. PubMed ID: 22972985
[TBL] [Abstract][Full Text] [Related]
12. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
Front Immunol; 2021; 12():704526. PubMed ID: 34497607
[TBL] [Abstract][Full Text] [Related]
13. IL-12/IL-18-preactivated donor NK cells enhance GVL effects and mitigate GvHD after allogeneic hematopoietic stem cell transplantation.
Song Y; Hu B; Liu Y; Jin Z; Zhang Y; Lin D; Zhu Y; Lei L; Gong H; Mei Y; Teo HY; Wu D; Liu H
Eur J Immunol; 2018 Apr; 48(4):670-682. PubMed ID: 29282719
[TBL] [Abstract][Full Text] [Related]
14. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
[No Abstract] [Full Text] [Related]
16. Combination of anti-CD4 antibody treatment and donor lymphocyte infusion ameliorates graft-versus-host disease while preserving graft-versus-tumor effects in murine allogeneic hematopoietic stem cell transplantation.
Ueha S; Yokochi S; Ishiwata Y; Kosugi-Kanaya M; Shono Y; Shibayama S; Ito S; Matsushima K
Cancer Sci; 2017 Oct; 108(10):1967-1973. PubMed ID: 28787768
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of JAK-STAT Signaling by Baricitinib Reduces Interferon-γ-Induced CXCL10 Production in Human Salivary Gland Ductal Cells.
Aota K; Yamanoi T; Kani K; Ono S; Momota Y; Azuma M
Inflammation; 2021 Feb; 44(1):206-216. PubMed ID: 32772240
[TBL] [Abstract][Full Text] [Related]
18. Baricitinib counteracts metaflammation, thus protecting against diet-induced metabolic abnormalities in mice.
Collotta D; Hull W; Mastrocola R; Chiazza F; Cento AS; Murphy C; Verta R; Alves GF; Gaudioso G; Fava F; Yaqoob M; Aragno M; Tuohy K; Thiemermann C; Collino M
Mol Metab; 2020 Sep; 39():101009. PubMed ID: 32413585
[TBL] [Abstract][Full Text] [Related]
19. A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro.
Murakami K; Kobayashi Y; Uehara S; Suzuki T; Koide M; Yamashita T; Nakamura M; Takahashi N; Kato H; Udagawa N; Nakamura Y
PLoS One; 2017; 12(7):e0181126. PubMed ID: 28708884
[TBL] [Abstract][Full Text] [Related]
20. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
